- Ends in
- 🎉 50% off + 10% extra. Ends in
24:00:00
The thymosin family breaks into three classification groups based on isoelectric point: alpha (below pH 5.0), beta (pH 5.0–7.0), and gamma (above pH 7.0). Despite sharing a name, these groups are structurally and genetically unrelated, a fact that catches many researchers off guard. The naming reflects their co-isolation from thymus tissue in the 1960s, not any shared molecular ancestry.
The three variants that matter most for research and therapeutic work are:
At least 15 beta-thymosin variants have been identified to date, though only Tβ4 and Tβ10 are expressed in healthy human tissue. Tβ15 is the outlier, present exclusively in pathological contexts.
Tα1 and Tβ4 are studied in almost entirely separate research domains, and for good reason. Their mechanisms do not overlap.
Tα1 is a biological response modifier. It activates T-cells, natural killer cells, and dendritic cells, and it modulates cytokine production without triggering the overstimulation associated with agents like interferon alpha. Endogenous serum concentrations in healthy adults are measurable, with variable reported levels. Clinically, it is sold under the brand name Zadaxin and has been approved in multiple countries for hepatitis B, hepatitis C, and certain cancers.
Tβ4 works through a completely different pathway. Its primary function is actin sequestration and cell migration, which drives wound healing, angiogenesis, and tissue regeneration. It binds G-actin monomers, preventing polymerization and giving cells the cytoskeletal flexibility needed for migration and repair. Hair growth researchers have also documented Tβ4’s role in follicle activation, an effect discovered incidentally during wound healing studies.
“Thymosin peptides activate the immune system through several mechanisms and signalling pathways, including stimulation of T-cell differentiation and maturation, activation of NK and DC cells, and induction of the release of proinflammatory cytokines. As modulators, they act as both pro- and anti-inflammatory factors.” — International Journal of Peptide Research and Therapeutics, 2024
Tβ10 shares structural homology with Tβ4 and influences cytoskeletal organization, but its research profile is thinner. Tβ15 is the most clinically distinct: it associates with non-small cell lung cancer progression, metastasis, and upregulation in breast and prostate malignancies. Healthy tissue does not express it at all.
The “thymosin” name creates a persistent misconception that these peptides are thymus-exclusive. They are not. Tβ4 is highly expressed across multiple tissues including the brain, liver, kidney, myocardium, platelets, and leukocytes. Tα1 has been detected in the spleen, lung, kidney, brain, and blood, with its highest concentrations in thymic epithelial cells.
The systemic reach of these peptides matters for how you interpret research findings:
Thymic peptides secreted into systemic circulation also interact with the hypothalamic-pituitary-adrenal axis, with concentrations fluctuating in line with circadian corticosteroid rhythms. That connection to the HPA axis places thymosins at the intersection of immune function and broader metabolic regulation, an area Synthrolab’s research into metabolic modulation covers in depth.
One of the most common errors in thymosin research is treating the alpha and beta groups as structurally related simply because they share a name. They are not. The classification was based on isoelectric focusing behavior during the original isolation of Thymosin Fraction 5, not on sequence homology or shared genetic origin. Researchers who conflate Tα1’s immune mechanisms with Tβ4’s cytoskeletal functions end up designing protocols that answer the wrong question.
Synthrolab supplies research-grade synthetic analogs including TB-500, a synthetic form of Tβ4 that retains biological activity with improved stability over the native peptide. Thymopentin, derived from thymopoietin’s active fragment (residues 32–36), follows the same principle: a shorter, more stable analog that preserves the functional core. Both are practical tools when native peptide stability is a limiting factor in experimental design.
Pro Tip: When selecting between Tα1 and Tβ4 analogs for a study, define your endpoint first. Immune cell activation studies call for Tα1; wound healing, angiogenesis, or cytoskeletal research calls for Tβ4. Using the wrong variant produces real data for the wrong mechanism.
Researchers sourcing TB-500 for cytoskeletal and regeneration studies can find Synthrolab’s BPC-157 and TB-500 combination product, which is designed for studies examining overlapping repair pathways.
Choosing the right variant for a study or therapeutic application depends on understanding what each one actually does, not just what family it belongs to.
Tβ15’s cancer-specific expression sets it apart from every other variant in this family. Tβ4’s regenerative profile is the broadest. Tα1 remains the most clinically validated, with approved therapeutic use across multiple countries under the Zadaxin brand.
Tα1 is produced as a cleavage product of prothymosin alpha (ProTα), a 109-amino acid nuclear protein. The enzyme asparaginyl endopeptidase cleaves ProTα to generate the active 28-residue Tα1 fragment. Tβ4 is encoded by a separate gene and synthesized as a complete peptide, not a precursor fragment. The TMPO gene encodes thymopoietin through alternative splicing, producing at least three isoforms with molecular weights of 75 kDa, 51 kDa, and 39 kDa.
For research-scale production, Tα1 used in clinical settings is synthesized entirely by solid-phase peptide synthesis, yielding a product chemically identical to endogenous human Tα1. Genetic engineering approaches using Escherichia coli and Pichia pastoris expression systems have also been explored as cost-reduction strategies, with concatemer constructs showing stronger lymphocyte proliferation activity in some in vitro models than single-unit synthetic peptide.
Tα1 (Zadaxin) has the deepest clinical record. It has been evaluated in randomized trials for hepatitis B, hepatitis C, non-small cell lung cancer, severe sepsis, and acute respiratory distress syndrome. In sepsis patients with lymphopenia specifically, Tα1 has shown capacity to reduce pro-inflammatory cytokine release and increase lymphocyte counts. Its safety profile is notably clean, with no significant toxicities reported even in long-term use.
Tβ4 clinical work focuses on tissue regeneration. Cardiac repair after myocardial infarction, corneal wound healing, and dry eye syndrome are among the active research areas. Its anti-fibrotic effects in liver injury models, where it reduces collagen deposition and suppresses interleukin-8 secretion, have drawn interest for chronic inflammatory conditions. Researchers exploring these cellular regeneration applications will find Tβ4 analogs the most relevant starting point.
Mass spectrometry (MS) is the gold standard for thymosin characterization. Hannappel et al. used MS to identify more than 100 peptides in Thymosin Fraction 5, a count far exceeding the 30 detected by earlier chromatographic methods. For quantification of Tα1 in serum, immunoassays are the standard clinical tool, with reliable detection down to the 0.1–1.0 ng/mL range seen in healthy adults.
Radioimmunoassay and enzyme-linked immunosorbent assay (ELISA) platforms have been used extensively for Tβ4 quantification in tissue samples. NMR spectroscopy has characterized the structural behavior of beta-thymosins, revealing that Tβ4 adopts helical conformations at residues 5–19 and 30–37 under low-temperature or mixed-solvent conditions, despite being largely unstructured at physiological temperature. That structural flexibility is likely central to how Tβ4 interacts with G-actin.
Tβ4 is one of the most evolutionarily conserved peptides known. Its sequence is essentially identical across mammals, from mice and rats to cattle, chimpanzees, and humans. That conservation across species is what makes rodent wound healing and cardiac models directly translatable to human research contexts.
Tα1 shows similarly high conservation in lymphoid tissues across vertebrates, consistent with its fundamental role in T-cell development. Tβ9, the bovine analog of human Tβ10, differs by only two amino acids, and the two peptides share nearly identical helical structure under experimental conditions. The evolutionary stability of these sequences across hundreds of millions of years of divergence suggests their core functions are under strong selective pressure.
The thymosin family contains structurally unrelated peptide groups classified by isoelectric point, not shared genetic origin, and each major variant requires variant-specific selection for research or therapeutic use.
| Point | Details |
|---|---|
| Tβ4 dominates beta-thymosins | Tβ4 accounts for 70–80% of total beta-thymosin content in humans. |
| Tα1 and Tβ4 have separate mechanisms | Tα1 activates immune cells; Tβ4 regulates actin and tissue repair. |
| Tβ15 signals pathology | Tβ15 is absent in healthy tissue and upregulated in prostate, breast, and lung cancers. |
| Groups are genetically unrelated | Alpha, beta, and gamma thymosins share a name but not a genetic or structural origin. |
| Synthetic analogs extend research utility | TB-500 and thymopentin retain biological activity with improved stability over native peptides. |
21+ verification
All products are sold strictly for laboratory research use only and are not for human or animal consumption. You must be 21 or older to enter.
By entering you accept the research-use-only terms and confirm you are a qualified buyer.
